Main content
Debate over life-extending cancer drug
Experts and cancer patients debate whether advisory body NICE should allow breast cancer drug Kadcyla to be available to NHS patients in England.
Advisory body NICE is reviewing drugs made available through the old cancer drugs fund, and has rejected Kadcyla for use on the NHS in England.
It believes the price per patient set by manufacturer Roche is too expensive. Roche says discussions are continuing.
Duration:
This clip is from
More clips from 16/01/2017
-
![]()
Cancer patients' distress over drug access
Duration: 15:11
-
![]()
The dads who chose their kids over work
Duration: 30:00
More clips from Victoria Derbyshire
-
![]()
Coronavirus: Inside a UK GP surgery battling the outbreak
Duration: 06:27
-
![]()
'My anti-depressant withdrawal was worse than depression'
Duration: 08:58
-
![]()
Menstrual cup misuse 'can cause pelvic organ prolapse'
Duration: 05:23
-
![]()
Rough sleepers: 'No-one ever asks how lonely we are'
Duration: 14:50
